Aprea Therapeutics Cancer Therapy Platform Is Promising

Jul. 21, 2020 3:48 PM ETAprea Therapeutics, Inc. (APRE)13 Comments
William Meyers profile picture
William Meyers


  • Aprea IPO'd in October 2019.
  • Its therapies for cancer work on the p53 protein, Guardian of the Genome.
  • Results are promising so far, and stock price is reasonable.

Aprea Therapeutics (NASDAQ:APRE) is a clinical stage biotechnology company with a promising cancer drug that is in a Phase 3 study that should report out preliminary data late in 2020. If the drug, eprenetapopt, shows positive results, it could get approved by regulatory agencies and, with further trials, get its label expanded to other cancers. Aprea's stock has only been available for public purchase since its IPO in October 2019.

Because I had bought a considerable (for me) amount of Inovio (INO) for as low as $2.43 in 2019, and it went up as high as $33.79 this year, I have been rebalancing my portfolio (I don't like any one stock to be over 10% of the portfolio). I have accumulated some cash in case the pandemic crashes the market, bought more of some of the other stocks in my portfolio, bought some non-biotech dividend stocks, and added two biotechs to my portfolio, Aprea and Arrowhead (ARWR). This article is my first on Aprea. I will explain why I bought it. Which is, of course, that I think that while there are risks, it has a good chance of becoming a much larger pharmaceutical company in this decade. Or it may be bought out by one of the larger companies looking for a way to quickly add to their commercial-stage cancer drug portfolio.

ChartData by YCharts


Cancer has complex causes, commonly including many possible mutations in the chromosomes of a cell that allow it to start growing in an unregulated fashion. The body has many mechanisms to eliminate cancer cells, some of them external to the cell, some of them internal. P53 is a protein, sometimes called the Guardian of the Genome, that acts as a tumor suppressor. In its healthy, or wild, form, it prevents mutations. It also can kill the cell (apoptosis) if it is unable

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is openicon.com, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Disclosure: I am/we are long APRE, INO, CLSN, ARWR. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (13)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.